Antiviral Therapy 2014; 19: (doi: /IMP2718)
|
|
- Judith Marshall
- 6 years ago
- Views:
Transcription
1 Antiviral Therapy 2014; 19: (doi: /IMP2718) Original article Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate Marc Bifano 1 *, Heather Sevinsky 1, Carey Hwang 2, Hamza Kandoussi 3, Hao Jiang 3, Dennis Grasela 1, Richard Bertz 1 1 Research and Development, Bristol Myers Squibb, Hopewell, NJ, USA 2 Research and Development, Bristol Myers Squibb, Princeton, NJ, USA 3 Research and Development, Bristol Myers Squibb, Lawrenceville, NJ, USA *Corresponding author marc.bifano@bms.com Background: Daclatasvir is a highly selective NS5A replication complex inhibitor currently in development for the treatment of chronic hepatitis C infection. Daclatasvir is active at picomolar concentrations and demonstrates in vitro activity against a broad range of HCV genotypes. The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen ). Methods: In this open-label single-sequence study, 20 healthy female subjects received ethinyl estradiol and norgestimate for three cycles, with coadministration of daclatasvir in cycle 3. Pharmacokinetics of ethinyl estradiol and the active metabolites of norgestimate (norelgestromin and norgestrel) were assessed in cycles 2 and 3. Results: Adjusted ratios of geometric means and 90% CIs were estimated for the maximum observed plasma concentration (ethinyl estradiol 1.11 [1.02, 1.20], norelgestromin 1.06 [0.99, 1.14] and norgestrel 1.07 [0.99, 1.16]) and area under the plasma concentration time curve in one dosing interval (ethinyl estradiol 1.01 [0.95, 1.07], norelgestromin 1.12 [1.06, 1.17] and norgestrel 1.12 [1.02, 1.23]). Conclusions: Coadministration of daclatasvir resulted in no clinically relevant effects on exposure to ethinyl estradiol, norelgestromin or norgestrel. Introduction Up to 170 million individuals are chronically infected with HCV worldwide [1]. Chronic HCV infection is a common cause of chronic progressive liver disease and hepatocellular carcinoma [2]. Until recently, treatment with pegylated interferon (PEG-IFN)-a and the nucleoside analogue ribavirin (RBV) was the standard of care in the management of chronic HCV infection. However, sustained virological response (SVR) rates with this regimen vary depending on viral load, HCV genotype, patient demographics, disease history and host genetics. Although SVR rates of 80% can be achieved in previously treatment-naive patients with HCV genotype 2 or 3 [3,4], SVR rates are lower among those with HCV genotype 1 (40 50%) [5], and in patients with prior nonresponse to PEG-IFN-a/RBV (6 9%). PEG-IFN-a/RBV treatment is also associated with significant haematologic toxicity and frequent side effects, such as flu-like symptoms, haemolytic anaemia, fatigue and depression [4]. The recent introduction of the HCV non-structural protein 3 (NS3) protease inhibitors, telaprevir and boceprevir, which are approved for use in combination with PEG-IFN-a/RBV for the treatment of chronic HCV genotype 1 infection, has significantly improved SVR rates in treatment-naive patients with HCV genotype 1 infection to approximately 70 75% [6,7]. However, both of these direct-acting antivirals increase the frequency and/or severity of adverse events (AEs) compared with that observed with PEG-IFN-a/RBV treatment alone. Boceprevir is associated with increased rates of anaemia and dysgeusia [8], and telaprevir with elevated rates of rash, pruritis, nausea and anaemia [9]. In addition to their clinical AE profiles, both boceprevir and telaprevir are substrates and significant inhibitors of cytochrome (CY) P450 3A (CYP3A), and are known (telaprevir) or inferred (boceprevir) to be substrates and inhibitors of the P-glycoprotein 1 (PgP) 2014 International Medical Press (print) (online) 511
2 M Bifano et al. transporter [10]. As a result, both drugs are associated with a number of pharmacokinetic interactions with concomitant medications, and are contraindicated for use with CYP3A substrates, for which elevated systemic exposure is associated with an increased risk of serious AEs [8,9]. For example, telaprevir has been shown to increase the maximum observed plasma concentration ( ) and area under the plasma concentration time curve (AUC) of both cyclosporine and tacrolimus when coadministered in healthy subjects as a result of telaprevir-induced CYP3A4 inhibition [11]. In addition, telaprevir and boceprevir have also been shown to reduce exposure to a number of drugs by increasing their metabolism, thus resulting in reduced efficacy [8,9]. One such pharmacokinetic interaction noted for both telaprevir and boceprevir is a reduction of ethinyl estradiol (EE) levels when taken with hormonal contraceptives, and, as a result, a warning has been issued for both drugs advising that hormonal contraception may be unreliable during (and, in the case of telaprevir, for up to 2 weeks after) treatment [8,9]. EE and norgestimate (NGM; Ortho Tri-Cyclen, Ortho-McNeil Pharmaceutical Inc., Raritan, NJ, USA) is a commonly prescribed combination oral contraceptive containing EE and the synthetic progestin NGM, which is converted in vivo to its active metabolites norelgestromin (NGMN) and norgestrel (NG). EE is subject to extensive first-pass metabolism in both the gut and the liver, with sulfate conjugation via sulfotransferase 1E1 in the gut, contributing to approximately 60% of the first-pass effect. Once absorbed, EE is also hydroxylated by CYP3A4 and CYP2C9, with CYP2C8, CYP2C19 and CYP1A2 contributing to a lesser extent [12 14], and is glucuronidated by uridine diphosphate glucuronyltransferase (UGT) 1A1 [15]. The basis of the interaction between EE and telaprevir or boceprevir is not fully understood, but may be a multifactorial effect resulting from alterations in CYP450 activity, direct or indirect effects on UGT or sulfation, or alterations in gastrointestinal transport mechanisms. The enzymes responsible for the metabolism of NGM and its active metabolites have not been fully characterized, but it is thought that both CYP3A4 and UGTs may also be involved. The significant teratogenicity of RBV (a pregnancy category X drug) renders it contraindicated for use in pregnancy and makes effective contraception vital in women of childbearing potential who are undergoing PEG-IFN-a/RBV-containing treatment for chronic HCV infection. Thus the effects of telaprevir and boceprevir on EE-based contraceptives necessitate the use of two non-hormonal methods while the interaction is still in effect [8,9]. A number of other direct-acting antivirals for chronic HCV infection are in clinical development. Among them is daclatasvir (DCV; BMS ), which is a highly selective, first-in-class inhibitor of HCV NS5A, an essential component of the HCV replication complex [16,17]. DCV inhibits multiple functions of NS5A, which may explain its potent antiviral effect in vitro; DCV is active at picomolar concentrations and demonstrates in vitro activity against a broad range of HCV genotypes [18]. DCV has previously demonstrated rapid virological suppression, high SVR rates and good tolerability in combination with PEG-IFN-a/RBV among treatment-naive patients with HCV genotype 1 [19]. Clinical efficacy with DCV has also been observed in combination with asunaprevir, an NS3 protease inhibitor and the non-nucleoside inhibitor BMS [20], as well as in combination with the nucleotide inhibitor sofosbuvir (GS-7977) with and without RBV [21]. High SVR rates are also achievable in HCV genotype 1b patients with a prior null response to PEG-IFN-a/RBV when DCV is used in combination with asunaprevir [22,23]. Preclinical data indicate that DCV is a substrate and inhibitor of PgP and a substrate for CYP3A4; in vivo studies with the CYP3A4 probe substrate midazolam suggest that DCV is unlikely to alter the pharmacokinetics of CYP3A4 substrates (Bristol Myers Squibb, unpublished data). Therefore, unlike telaprevir and boceprevir, DCV has a lower potential for causing drug drug interactions with drugs that are metabolized via the CYP450 pathway. We herein describe a study evaluating the steady-state pharmacokinetic effects of DCV (60 mg once daily) on the active components (EE, NGMN and NG) of a concomitant combined oral contraceptive in healthy female volunteers, along with the tolerability and safety of this drug combination. Methods Study design This was an open-label, three-cycle (lead-in cycle [cycle 1], cycle 2 and cycle 3), single sequence study in 20 healthy women of childbearing potential (clinicaltrials.gov identifier NCT ; Figure 1). Screening evaluations were undertaken to determine eligibility within 28 days prior to the start of the lead-in cycle (day 1). The evening prior to dosing (day 1), subjects were admitted to the clinical facility and underwent baseline evaluations. On day 1, subjects entered the lead-in cycle to ensure compliance and to synchronize subjects to the same dosing schedule. The lead-in cycle and cycle 2 consisted of a standard dosing schedule: daily administration in a 4-week (3 weeks on, 1 week off) cycle, in which the EE dose remains constant at 35 mg while NGM is given on an ascending dose schedule of 180 mg during week 1, 215 mg during week 2 and 250 mg during week 3. The International Medical Press
3 Pharmacokinetics of daclatasvir and an oral contraceptive Figure 1. Study design Treatment A: Days 1 28 Lead-in cycle (Cycle 1) Treatment B: Days Cycle 2 PK sampling on day 49 for 24 h Treatment C: Days DCV 60 mg once daily (Days only) Cycle 3 PK sampling on day 77 for 24 h Subjects received a combined oral contraceptive on days 1 28 (lead-in cycle; treatment period A), days (cycle 2; treatment period B) and days (cycle 3; treatment period C), with daclatasvir (DCV) coadministration on days , ethinyl estradiol and norgestimate; PK, pharmacokinetic. final study cycle (cycle 3) spanned only the 3 weeks of active dosing. During this cycle, DCV was administered for 10 days in combination with EE/ NGM during days DCV was dosed at 60 mg once daily, the highest anticipated therapeutic dose. A dose of 60 mg DCV was based on previous clinical experience and is within the projected therapeutic range known to be well tolerated. Pharmacokinetic sampling was undertaken on the last day of active dosing during cycles 2 and 3, when subjects were receiving the highest ascending dose of NGM (250 mg). Pregnancy testing, drug screening and assessment of treatment compliance were undertaken at the clinical centre at each scheduled visit after day 1 (days 28, 48, 56 and 67). During the lead-in cycle, subjects received their initial (day 1) dose at the clinical centre and thereafter continued dosing on an outpatient basis through to day 28. During cycle 2, dosing was on an outpatient basis except during days 48 50, when subjects remained at the clinical centre for assessment and 24-h pharmacokinetic sampling (pre-dose to pre-dose on days 49 50). During cycle 3, subjects received on an outpatient basis through to day 67. Subjects returned to the centre on day 67 and remained throughout the period of DCV dosing (that is, days 68 77). On days 77 78, 24-h pharmacokinetic sampling (pre-dose to pre-dose) was undertaken. Written informed consent was obtained from all patients prior to study procedures. The study was approved by the institutional review board of the study centre and was conducted in compliance with the Declaration of Helsinki, Good Clinical Practice Guidelines and local regulatory requirements. Inclusion and exclusion criteria Healthy female subjects aged 18 to 45 years with a body mass index (BMI) of kg/m 2 and intact ovarian function were eligible for enrolment into the study. Subjects had to be receiving a stable regimen of for 3 months prior to enrolment without evidence of breakthrough bleeding, or receiving a stable regimen of a different combined oral contraceptive for 3 months prior to the study and willing to switch to for 3 months during the study. Subjects were also required to have documented, acceptable Pap smear results within 1 year prior to day 1 of the study. A negative pregnancy test within 24 h prior to the start of study medication for each cycle was also required. Subjects were required to use an acceptable barrier method of contraception during the entire study through to 4 weeks after the study. Pharmacokinetic assessment Pharmacokinetic assessments were performed at steady state and pharmacokinetic evaluations were based on the concentration of study drugs in plasma at the given time points in the study. The levels of EE, NG and NGMN in human plasma were assayed using validated liquid chromatography with tandem mass spectrometry. Following a liquid liquid extraction procedure, analyte concentrations were calculated with a 1/x 2 linear regression over a concentration range of pg/ml for EE, ng/ml for NGMN and 50 25,000 pg/ml for NG and their internal standards (17a-ethynylestradiol-2,4,16,16-d4, desacetylnorgestimate-d5 and norgestrel-d5, respectively). All measurements were performed during the period of known analyte stability. Pharmacokinetic parameters were derived from plasma concentration-versus-time data and included the following:, time of maximum observed plasma concentration (T max ) and AUC in one dosing interval ( ). Plasma concentration-versustime data were analysed by non-compartmental methods using the program Kinetica (version 4.4.1; Adept Scientific, Letchworth Garden City, Herts, UK). Actual sample collection times were used for pharmacokinetic calculations. Predose concentrations and concentrations prior to the first quantifiable concentration that were below the lower limit of quantification were treated as missing for the calculation of summary statistics. The and T max were recorded directly from experimental observations; was calculated by log- and linear-trapezoidal calculations. Summary statistics for relevant pharmacokinetic parameters of each analyte were tabulated by treatment. To assess the effect of concomitant administration of DCV on EE, NGMN and NG, and mixedeffect models were fitted to log-transformed data with treatment as a fixed effect and measurements within Antiviral Therapy
4 M Bifano et al. each subject as repeated measurements. Log-scale point estimates and 90% CIs for treatment differences were subsequently exponentiated to obtain estimates on the original scale. If the 90% CIs for the geometric mean ratios (GMRs) for parameters obtained with versus without concomitant DCV were entirely contained within the conventional bioequivalence range of , then an absence of DCV effect on the pharmacokinetics of each analyte was concluded. No adjustments were made for multiplicity. All statistical analyses were carried out using SAS/STAT software (version 8.2; SAS Institute Inc., Cary, NC, USA). Safety assessments Subjects were closely monitored for AEs throughout the study. Physical examinations, vital sign measurements, 12-lead electrocardiograms (ECG) and clinical laboratory evaluations were performed at selected times throughout the study. Safety measurements were based on the results of these evaluations and on medical review of AE reports. Results Subjects A total of 20 women were enrolled and received EE/ NGM. Of these, 18 subjects completed the study. All subjects were Caucasian, with a mean age of 29.8 years (range 18 44) and a mean BMI of 24.0 kg/m 2 (range ) at screening. Pharmacokinetics of EE, NGMN and NG Mean 24 h steady-state plasma concentration time profiles for EE (Figure 2A), NGMN (Figure 2B) and NG (Figure 2C) following repeated dosing of with (day 77) and without (day 49) DCV are shown. For all analytes, peak values were reached 2 h post-dose and returned to baseline by 24 h post-dose. Individual intra-subject changes in and for dosing with and without DCV are shown for all three analytes (Figure 3). A slight increase in EE was observed in the majority of patients during coadministration of DCV (Figure 3A), but with no clear pattern observed for (Figure 3B). For NGMN and NG, a slight increase in was observed in most subjects, with no clear pattern observed for (Figure 3C 3F). Statistical comparisons of the geometric mean values for and (0 24 h post-dose) are shown for all three analytes (Table 1). In all cases, the 90% CIs for the GMRs for dosing with versus without concomitant DCV fell within the pre-specified range denoting no interaction ( ). GMR 90% CI lower boundaries for EE, NGMN and NG were 1.02, 1.06 and 1.02, respectively, indicating small increases in exposure when DCV was coadministered with EE/ NGM; however, the upper boundaries remained within the pre-defined no-effect range. Safety No serious AEs were reported. One subject discontinued study treatment as a result of back injury, which was not related to study treatments. Another subject discontinued for personal reasons. The most common AEs (those occurring in 10% of patients during any treatment period) are shown (Table 2). All AEs reported throughout the treatment periods were classified as mild in intensity. The most common AEs were headache, metrorrhagia, constipation and back pain. All subjects who experienced metrorrhagia (30% of total subjects) throughout the treatment periods had switched to from other oral contraceptives. All subjects who also experienced metrorrhagia during treatment period C (days 68 77; DCV coadministration) had experienced this AE during earlier treatment periods. No laboratory AEs were reported and no evidence of clinically meaningful effects on physical examinations, ECGs or vital sign measurements were observed. Discussion Pharmacokinetic interactions with oral contraceptives that necessitate additional or alternative methods of birth control during treatment are common among drugs with significant inhibitory or inductive effects on CYP3A4 and/or UGT. These include many HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors [24], which, unlike the finite HCV treatments, require life-long administration. Oral contraceptive failure or reductions in efficacy are frequent causes of unwanted pregnancy or breakthrough bleeding, and may result from drug drug interactions that increase EE or NGM metabolism. For example, studies of the HIV protease inhibitors atazanavir and darunavir in combination with ritonavir reduce EE exposures [25,26]. Although ritonavir is both an inhibitor of CYP3A4 and an inducer of UGT, through activation of the pregnane x receptor, the increased clearance of EE with coadministration of ritonavir suggests that clearance via UGT may be more important in the disposition of EE than CYP3A4 [27,28]. The anticonvulsant carbamazepine is also a known inducer of UGT and CYP3A4 [29]. Coadministration of carbamazepine with an EE-containing oral contraceptive results in reduced EE exposures, and increased ovulation and breakthrough bleeding, compared with that observed with administration of the oral contraceptive alone [30]. The currently approved direct-acting HCV antivirals, telaprevir and boceprevir, are significant inhibitors and International Medical Press
5 Pharmacokinetics of daclatasvir and an oral contraceptive Figure 2. Mean plasma concentration time profiles of ethinyl estradiol, norelgestromin and norgestrel A 200 on day 49 +DCV 60 mg once daily on day Concentration, pg/ml B Concentration, ng/ml C Time, h Time, h 4,000 3,500 Concentration, pg/ml 3,000 2,500 2,000 1,500 1, Time, h Mean (±sd) plasma concentration time profiles of (A) ethinyl estradiol, (B) norelgestromin and (C) norgestrel when a combined oral contraceptive is administered alone (day 49) and in combination with the NS5A replication complex inhibitor daclatasvir (DCV; 60 mg once daily, day 77) in healthy female subjects., ethinyl estradiol and norgestimate. Antiviral Therapy
6 M Bifano et al. Figure 3. and plots for ethinyl estradiol, norelgestromin and norgestrel A, pg/ml DCV Cmax, pg/ml B, pg h/ml 1,900 1,700 1,500 1,300 1, DCV 1,900 1,700 1,500 1,300 1, , pg h/ml C, ng/ml DCV Cmax, ng/ml D, ng h/ml DCV, ng h/ml E, pg/ml 5,000 4,000 3,000 2,000 1, DCV 5,000 4,000 3,000 2,000 1,000 0 Cmax, pg/ml F, pg h/ml 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10, ,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 +DCV, pg h/ml Individual maximum observed plasma concentration ( ) and area under the plasma concentration time curve in one dosing interval ( ; 0 24 h post-dose) plots for (A&B) ethinyl estradiol, (C&D) norelgestromin and (E&F) norgestrel when a combined oral contraceptive is administered alone (day 49) and in combination with the NS5A replication complex inhibitor daclatasvir (DCV; 60 mg once daily; day 77) in healthy female subjects., ethinyl estradiol and norgestimate International Medical Press
7 Pharmacokinetics of daclatasvir and an oral contraceptive Table 1. Pharmacokinetic comparisons of ethinyl estradiol, norelgestromin and norgestrel for a combined oral contraceptive containing dosed with versus without concomitant DCV GMR (90% CI), with Adjusted geometric means alone (day 49) +DCV (day 77) versus without DCV Ethinyl estradiol, pg/ml (1.02, 1.20), pg h/ml (0.95, 1.07) Norelgestromin, ng/ml (0.99, 1.14), ng h/ml (1.06, 1.17) Norgestrel, pg/ml 2, , (0.99, 1.16), pg h/ml 47, , (1.02, 1.23), area under the plasma concentration time curve in one dosing interval (0 24 h post-dose);, maximum observed plasma concentration; DCV, daclatasvir;, ethinyl estradiol and norgestimate; GMR, geometric mean ratio. Table 2. Summary of adverse events occurring in 10% patients in any treatment period Treatment period A Treatment period B Treatment period C +DCV Adverse event days 1 28 a days a days a days b days b Headache 4 (20.0) 2 (10.0) 6 (30.0) 0 3 (16.7) Metrorrhagia 5 (25.0) 1 (5.0) 1 (5.0) 0 3 (16.7) Constipation (22.2) Back pain 0 1 (5.0) (16.7) Nausea (10.0) 0 1 (5.6) Irregular menstruation 2 (10.0) 0 1 (5.0) 0 0 Acne (11) 0 Abdominal pain 2 (10.0) Data are n (%). a n=20. b n=18. DCV, daclatasvir;, ethinyl estradiol and norgestimate. substrates of CYP3A4 and have been demonstrated to increase exposure to a number of CYP3A4 substrates, including the calcineurin inhibitors cyclosporine and tacrolimus, when coadministered with telaprevir [11]. By contrast, coadministration of telaprevir and an EE/ norethindrone containing contraceptive results in a 26% reduction in EE, 28% reduction in EE AUC, and 33% reduction in EE C min, which may be due to telaprevir increasing first-pass metabolism of EE in the gastrointestinal tract by affecting transporters involved in the absorption of EE [31]. Similarly, boceprevir also reduces EE AUC by 24%, while increasing the and AUC of the synthetic progestin drospirenone by 99% and 57%, respectively, substantially increasing the risk of drospirenone-related AEs [10]. The drug drug interactions observed between telaprevir and boceprevir and EE-based contraceptives necessitate the use of two nonhormonal methods of contraception during, and for telaprevir up to 2 weeks after, treatment. Ongoing clinical development of other direct-acting antivirals for HCV infection requires that their potential for drug interactions with concomitant medications is investigated. Knowledge of their oral contraceptive interactions is vital given the known teratogenic and embryocidal potential of RBV and the likelihood that these newer agents will frequently be used in PEG IFN a/ RBV-containing combinations. Few studies specifically discuss what constitutes a subtherapeutic level of EE. However, most oral contraceptives typically contain EE at a dose of µg, with low-dose contraceptives containing µg of EE. Furthermore, it is not uncommon for upward dose titration to occur in the context of low-dose EE for breakthrough bleeding. Therefore, any drug drug interactions resulting in EE levels less than those achieved with a 20 µg dose are likely to result in reduced efficacy, and potentially breakthrough bleeding [25]. In addition, it is generally accepted that even minor decreases (arbitrary definition 20% reduction in exposure; equivalent to a decrease from 30 µg to 20 µg of EE) in EE and may result in a loss of contraceptive efficacy; therefore, where this occurs, patients are advised to use non-hormonal methods of contraception to prevent pregnancy [32]. Antiviral Therapy
8 M Bifano et al. The main objective of this study was to assess the effect of the investigational NS5A replication complex inhibitor DCV on the pharmacokinetics of EE and NGMN, the primary active components of a combined oral contraceptive, in healthy female subjects. Previously, DCV has demonstrated weak time-dependent inhibition of CYP3A4 in vitro, although subsequent in vitro work identified a low potential for CYP3A4 induction based on increased CYP3A4 messenger RNA activity in human hepatocytes (Bristol Myers Squibb, unpublished data). Results from a clinical study assessing the impact of DCV on the pharmacokinetics of the CYP3A4 substrate midazolam demonstrated that DCV is unlikely to have a clinically significant impact on exposures to CYP3A4 substrates (Bristol Myers Squibb, unpublished data). The potential for an interaction between DCV and substrates of sulfotransferase or UGTs has not been investigated. Unlike the reductions in EE exposure observed with concomitant telaprevir and boceprevir, in the current study only small increases (6 11% increase in GMR) in the of EE, NGMN and NG were observed with combined dosing of and DCV, and, similarly, modest increases (approximately 12%) in the of NGMN and NG. All comparisons fell within the prespecified range for no effect (90% CIs for GMRs contained within the conventional bioequivalence range of ), indicating that DCV does not have any clinically relevant effects on any active component of. In addition, coadministration of DCV with did not increase the frequency of metrorrhagia observed or change the individuals affected during cycle 3 compared with the administration of alone (cycles 1 and 2), suggesting maintenance of contraceptive efficacy of during DCV coadministration. Administration of DCV in combination with a combined oral contraceptive was also well tolerated in this study, with no serious or life-threatening AEs or AE-related discontinuations. Most AEs recorded were mild in intensity and were comparable to those observed during DCV monotherapy in HCV-infected patients [33]. Assessing the effect of anti-hcv drugs on the efficacy on oral contraceptives is a challenging undertaking. Most drug drug interaction studies investigate only two drugs at a time to enable interpretation of any changes in pharmacokinetic parameters. However, assessing the effect of anti-hcv drugs, including DCV, individually does not reflect their real-world application as part of combination treatment regimens, when there may be multiple layers of enzyme induction or inhibition as well as other physiologic effects that may alter drug absorption or excretion. Indeed, future assessments looking at combination DAAs and oral contraceptive drug drug interactions may be warranted to reflect the clinical use of these new agents. There are also disadvantages to conducting this, and other pharmacokinetic studies, in healthy HCV-negative subjects, who typically have lower BMIs and normal liver function compared with HCV-infected patients, which may have implications for drug metabolism and drug drug interactions. In addition, most drug drug interaction studies, including the current study, investigate only one type of oral contraceptive. Although the results from the current study suggest that DCV is unlikely to have any clinically meaningful effects on other EE-based oral contraceptives, it cannot be fully ascertained from the results presented herein that DCV will not have any effects on any other oral contraceptives that are currently available. In conclusion, the results of this study indicate that coadministration of DCV and an oral contraceptive containing EE and a progestin is well tolerated, does not result in clinically significant changes in exposure to either component, and hence, a loss of contraceptive efficacy due to a pharmacokinetic interaction is unlikely. Acknowledgements Editorial assistance was provided by Kate Gaffey of Articulate Science (Manchester, UK) and was funded by Bristol Myers Squibb. All authors wrote the manuscript. MB, DG and RB designed the research. MB, HS and CH analysed the data. HK and HJ contributed new reagents/ analytical tools. Disclosure statement All authors are employees of Bristol Myers Squibb. References 1. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31: Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through Ann Intern Med 2006; 144: Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: Druyts E, Mills EJ, Nachega J, O Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012; 5: Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: International Medical Press
9 Pharmacokinetics of daclatasvir and an oral contraceptive 7. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: Victrelis (boceprevir). Package insert Merck & Co., Inc., NJ, USA. 9. Incivek (telaprevir). Package insert Vertex Pharmaceuticals Incorporated, MA, USA. 10. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: Hirai S, Hussain A, Haddadin M, Smith RB. First-pass metabolism of ethinyl estradiol in dogs and rats. J Pharm Sci 1981; 70: Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 2004; 32: Ebner T, Remmel RP, Burchell B. Human bilirubin UDPglucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43: Bukh J, Pietschmann T, Lohmann V, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci US 2002; 99: Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: Pol S, Ghalib RH, Rustig VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: Accepted 26 November 2013; published online 17 December Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 8 June 2012). Available from Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther 2011; 16: Sekar VJ, Lefebvre E, Guzman SS, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther 2008; 13: Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A 2002; 99: Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 2011; 52: Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 2012; 52: Royal College of Obstetricians and Gynaecologists. Faculty of Sexual And Reproductive Healthcare clinical guidance. Drug interactions with hormonal contraception: clinical effectiveness unit. (Updated January Accessed October 2013.) Available from CEUguidancedruginteractionshormonal.pdf 33. Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS , an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: Antiviral Therapy
Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen
Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen Polina German, Maggie Wang, David Warren and Brian Kearney Gilead Sciences Foster City, CA,
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationEffect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationEffect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationT Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz
IN VIVO AND IN VITRO ASSESSMENT OF ASUNAPREVIR (ASV; BMS-650032) AS AN INHIBITOR AND SUBSTRATE OF ORGANIC ANION TRANSPORT POLYPEPTIDE (OATP) TRANSPORTERS IN HEALTHY VOLUNTEERS T Eley, Y-H Han, S-P Huang,
More informationHepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012
Reports From the Liver Meeting 212 Project ID: 521 Target Audience This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, physician assistants, and nurse practitioners
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationJOHNS HOPKINS HEALTHCARE
JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015
More informationBristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014
Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters Timothy Eley 15th HIV/HEPPK Workshop 21 May 2014 Disclosures T Eley is a full time employee and stockholder of Bristol-Myers
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationThe effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates
The effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates Varun Garg, PhD On behalf of Drs. N Adda, K Alves, G Chandorkar, J-E Lee, X Luo, F Smith, R van Heeswijk, and Y Yang Author
More informationPoster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA
Poster O_16 Lack of PK Interaction Between the HCV Protease Inhibitor MK-5172 and Methadone and Buprenorphine/Naloxone in Subjects on Stable Opiate Maintenance Therapy Iain Fraser, 1 Wendy W. Yeh, 1 Christina
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationErik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs Erik Mogalian, Polina German, Chris Yang, Lisa
More informationUPDATES IN HEPATITIS C
UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationRedefining The Math. The less the better WEEKS. Daclatasvir 60 mg Tablet K S
Redefining The Math 12 24 WEEKS W EE K S Hepatitis C; the most notorious of all hepatitis infections, has becoming a world threat due to its high morbidity and mortality rate. Moreover, with the prevalence
More informationMerck Sharp & Dohme Corp., The Netherlands; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; Yale University, New Haven, CT, USA;
Pharmacokinetic Interaction Between HCV Protease Inhibitor Boceprevir and Methadone or Buprenorphine/Naloxone in Subjects on Stable Maintenance Therapy Ellen GJ Hulskotte, 1 Hwa-Ping Feng, 2 R Douglas
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationSingle-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men
Citation: Clin Transl Sci (2017) 10, 480 486; C 2017 ASCPT. All rights reserved doi:10.1111/cts.12482 ARTICLE Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men LCaro 1, J de Hoon
More informationOriginal article Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1
Antiviral Therapy 2014; 19:501 510 (doi: 10.3851/IMP2731) Original article Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1 Namiki
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationThe Liver Meeting 2013: The 64th Annual Meeting of the AASLD Washington, DC, November 1 5, 2013 Presentation LB-1
Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection Everson GT,
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationONE REGIMEN, ALL GENOTYPES, 8 WEEKS
For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2010.03885.x Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationEvaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens Kimberly L. Garrison, Erik Mogalian, Heather Zhang, Grace Ma, Steve
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationPegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.08 Subsection: Anti-infective Agents Original Policy Date: January 1, 2006 Subject: Pegasys Ribavirin
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationAntivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond
Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures for
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationBruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University
Bruce A. Luxon, MD, PhD, FACG Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University Dr. Luxon is on the speakers p bureau
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationSingle and Multiple Dose Pharmacokinetics and Safety in Non-HIV-Infected Healthy Subjects Dosed with BMS , an Oral HIV Attachment Inhibitor
Single and Multiple Dose Pharmacokinetics and Safety in on-hiv-infected Healthy Subjects Dosed with 66368, an Oral HIV Attachment Inhibitor Richard ettles, Caly Chien, Erica Elefant, Xiaodong Wang, Ellen
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationProfessor David Back
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor David Back University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More information1. MEDICINAL PRODUCT FOR COMPASSIONATE USE
21 November 2013 Evaluation of Medicines for Human Use Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to member states for Daclatasvir
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationParent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins
Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationPENG Qin, TANG Shao-hui *, SHI Heng
504 2016 6 1 41 6 Meta [ ] (CHC) PubMed EMBASE The Cochrane Central Register of Controlled Trials CNKI CHC (RCTs) 2015 10 1 RevMan 5.3 Meta 6 RCT 1100 Meta(RVR) (cevr) (SVR 24 ) (P 0.0001) (60mg/d) RVR
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationDRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR
DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR Pharmacology NS3/4A protease inhibitor NS5A inhibitor Adult Dose Investigational: 100 mg once daily Investigational: 50 mg once daily Being developed as
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationA novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationMany promising small molecule inhibitors directed
GASTROENTEROLOGY 2012;142:1351 1355 Will Interferon-Free Regimens Prevail? Christoph Welsch Stefan Zeuzem Department of Internal Medicine I, J. W. Goethe University Hospital, Frankfurt/Main, Germany Many
More information